TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21667021

Group type: EXPERIMENTAL
Intervention: 1.0 μM all-trans retinoic acid (atRA) for 4 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1.0 μM 4-hydroxy-phenylretinamide (4-HPR) for 4 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1.0 μM 9-cis retinoic acid (9cRA) for 4 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: siRNA suppression of RARβ5 in BCA-2 cells
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: atRA treatment
Number of subjects: 9
Study: 19488979

Group type: EXPERIMENTAL
Intervention: Cloxazolam (test, Eurofarma Lab. Ltda)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olcadil (reference, Novartis Biociências S/A)
Number of subjects: 0
Study: 17130503

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 or 300 mg once daily)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 15142885

Group type: EXPERIMENTAL
Intervention: Filtered red blood cell transfusions
Number of subjects: 1051

Group type: COMPARATOR
Intervention: Non-filtered red blood cell transfusions
Number of subjects: 1051
Study: 11240108

Group type: COMPARATOR
Intervention: Normal elderly subjects
Number of subjects: 51

Group type: COMPARATOR
Intervention: PD patients
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Normal young subjects
Number of subjects: 51
Study: 9151069

Group type: EXPERIMENTAL
Intervention: 50% palatinose
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 37.5% palatinose + 12.5% xylitol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 50% xylitol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10% sucrose rinse
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: xylitol period
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: xylitol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no mouthrinses)
Number of subjects: 15
Study: 7855186

Group type: EXPERIMENTAL
Intervention: Citalopram treatment for 5 weeks after a 1-week wash-out and 1-week placebo period.
Number of subjects: 16
Study: 3324956

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 66

Group type: COMPARATOR
Intervention: Imipenem-cilastatin
Number of subjects: 66
Study: 29512517

Group type: EXPERIMENTAL
Intervention: Hybrid functional with a uniform parameter
Number of subjects: 0
Study: 25955823

Group type: EXPERIMENTAL
Intervention: Basic body awareness therapy (BAT)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Exercise therapy (ET)
Number of subjects: 113
Study: 23645162

Group type: EXPERIMENTAL
Intervention: VMAT-E
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IMRT-V
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: VMAT
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Elekta machine (IMRT and VMAT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: IMRT-E and IMRT-V
Number of subjects: 8

Group type: COMPARATOR
Intervention: VMAT-E and VMAT-V
Number of subjects: 8
Study: 23521461

Group type: EXPERIMENTAL
Intervention: Intraarticular injection of contrast agent mixed with 2% mepivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group received contrast agent only
Number of subjects: 120
Study: 20876826

Group type: EXPERIMENTAL
Intervention: Information about the Drug Burden Index (DBI) provided to general practitioners (GPs) via a letter and phone call, prompting cessation or dose reduction of anticholinergic and sedative medications.
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 115
Study: 18836789

Group type: EXPERIMENTAL
Intervention: 3‐h theory‐based behavioral HIV‐alcohol risk‐reduction intervention
Number of subjects: 353

Group type: COMPARATOR
Intervention: 1‐h HIV‐alcohol information/education control group
Number of subjects: 353
Study: 16622436

Group type: EXPERIMENTAL
Intervention: PVI gastrazole
Number of subjects: 116

Group type: COMPARATOR
Intervention: PVI placebo
Number of subjects: 116

Group type: COMPARATOR
Intervention: PVI fluorouracil (5‐FU)
Number of subjects: 116
Study: 12809173

Group type: EXPERIMENTAL
Intervention: GHRP-6 (2 microg/kg iv)
Number of subjects: 10

Group type: COMPARATOR
Intervention: DDAVP (10 microg iv)
Number of subjects: 10
Study: 12113193

Group type: EXPERIMENTAL
Intervention: Radiation treatment for ductal carcinoma in situ (DCIS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shorter radiation schedules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation for systemic metastases from breast cancer
Number of subjects: 0
Study: 9717655

Group type: EXPERIMENTAL
Intervention: Deep sclerectomy with collagen implant (DSCI)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard trabeculectomy
Number of subjects: 46
Study: 7993148

Group type: EXPERIMENTAL
Intervention: Aspirin (at least 95% adherence)
Number of subjects: 22071

Group type: EXPERIMENTAL
Intervention: Aspirin (taking < 50% of study tablets)
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Placebo (better adherence)
Number of subjects: 22071
Study: 3180636

Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide gel, 8 gm t.i.d.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30883054

Group type: EXPERIMENTAL
Intervention: Early cardioversion
Number of subjects: 427

Group type: COMPARATOR
Intervention: Delayed cardioversion
Number of subjects: 427
Study: 29390461

Group type: EXPERIMENTAL
Intervention: Ankle acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional needle manipulation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 90
Study: 25840298

Group type: EXPERIMENTAL
Intervention: Intralase iFS 150 kHz femtosecond laser
Number of subjects: 61

Group type: COMPARATOR
Intervention: Intralase FS 60 kHz femtosecond laser
Number of subjects: 61
Study: 23374986

Group type: COMPARATOR
Intervention: Biventricular (BV) repair
Number of subjects: 102

Group type: COMPARATOR
Intervention: 1.5-ventricle (1.5V) repair
Number of subjects: 102

Group type: COMPARATOR
Intervention: Univentricular (UV) repair
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All groups (BV, UV, 1.5V)
Number of subjects: 102
Study: 21127429

Group type: EXPERIMENTAL
Intervention: Automated BP measurement
Number of subjects: 44

Group type: COMPARATOR
Intervention: Manual BP measurement
Number of subjects: 44
Study: 19270030

Group type: EXPERIMENTAL
Intervention: Parent-Scored PSC administration
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Staff-Scored PSC administration
Number of subjects: 174

Group type: COMPARATOR
Intervention: Typical medical care control
Number of subjects: 174
Study: 17097958

Group type: EXPERIMENTAL
Intervention: Statin treatment (group 1)
Number of subjects: 58

Group type: COMPARATOR
Intervention: No statin treatment (group 0)
Number of subjects: 58
Study: 15271745

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSB) with 10 mL of 0.25% bupivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intraarticular local anesthetic (IA) with 20 mL of 0.25% bupivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISB) with 20 mL of 0.25% bupivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 11720825

Group type: EXPERIMENTAL
Intervention: Multimodal therapy (neoadjuvant chemotherapy, Patey mastectomy, postoperative radiotherapy and adjuvant hormone therapy)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Initial hormone therapy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both therapy groups
Number of subjects: 108
Study: 9035396

Group type: EXPERIMENTAL
Intervention: Gap detection for 50-Hz-wide markers in 0-dB/Hz noise
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gap detection for 1000-Hz-wide markers in 0-dB/Hz noise
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gap detection for 50-Hz-wide markers in 40-dB/Hz noise
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gap detection for 50-Hz-wide markers at equal SL's in 0-dB/Hz and 55-dB/Hz noise
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gap detection for markers presented at similar SLs across background noise levels
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gap detection related to marker-to-noise ratio
Number of subjects: 50
Study: 7895951

Group type: EXPERIMENTAL
Intervention: Hyperglycaemic clamping (plasma glucose approximately 15 mmol/l) with somatostatin suppression of insulin secretion
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Euglycaemic clamping (plasma glucose approximately 5 mmol/l) with somatostatin infusion
Number of subjects: 13
Study: 3312825

Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg twice daily)
Number of subjects: 173
Study: 31348308

Group type: EXPERIMENTAL
Intervention: General anesthesia + epidural anesthesia + Narcotrend D2
Number of subjects: 120

Group type: COMPARATOR
Intervention: General anesthesia + Narcotrend D1
Number of subjects: 120

Group type: COMPARATOR
Intervention: General anesthesia + Narcotrend D2
Number of subjects: 120

Group type: COMPARATOR
Intervention: General anesthesia + epidural anesthesia + Narcotrend D1
Number of subjects: 120

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural anesthesia at Narcotrend D2 depth
Number of subjects: 120
Study: 28603901

Group type: EXPERIMENTAL
Intervention: Testosterone administration (50 mg topical gel)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 103
Study: 25078052

Group type: EXPERIMENTAL
Intervention: Outpatient misoprostol administration (800 mcg intra-vaginally, eight hourly, maximum of three doses)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Inpatient misoprostol administration (800 mcg intra-vaginally, eight hourly, maximum of three doses)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Outpatient misoprostol administration
Number of subjects: 154

Group type: COMPARATOR
Intervention: Inpatient misoprostol administration
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Both outpatient and inpatient misoprostol administration
Number of subjects: 154
Study: 24280479

Group type: EXPERIMENTAL
Intervention: Music Intervention (MI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 21861719

Group type: EXPERIMENTAL
Intervention: Cinnamon 1,200 mg/day
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 19332203

Group type: EXPERIMENTAL
Intervention: Triple-antiplatelet therapy with cilostazol, aspirin, and clopidogrel
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Dual-antiplatelet treatment with aspirin and clopidogrel
Number of subjects: 1212
Study: 16783519

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute schizophrenia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic schizophrenia
Number of subjects: 0
Study: 15367413

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m² followed by epirubicin 80 mg/m² (group A)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Paclitaxel followed by carboplatin at an AUC of 6 mg x min/ml (group B)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Paclitaxel followed by carboplatin (group B)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Paclitaxel followed by epirubicin (group A)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment and cost analysis
Number of subjects: 327
Study: 11748315

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (20 Hz)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Low-frequency rTMS (5 Hz)
Number of subjects: 23
Study: 9195203

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous dexamethasone (1 mg/m2)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low-dose oral dexamethasone (2 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral clonidine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: GH-releasing hormone
Number of subjects: 14
Study: 8285649

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) - 400 kcal/day, only lean meat, fish, or fowl allowed
Number of subjects: 93

Group type: COMPARATOR
Intervention: Balanced Low Calorie Diet (LCD) - 1000-1200 kcal/day, all foods allowed in moderation
Number of subjects: 93
Study: 3557731

Group type: EXPERIMENTAL
Intervention: 200 mg labetalol daily for eight weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 400 mg labetalol daily for eight weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo for one week
Number of subjects: 21
Study: 29753994

Group type: EXPERIMENTAL
Intervention: Daily calorie restriction diet (22% daily reduction in energy needs)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intermittent calorie restriction diet (75% reduction in energy needs, 2 days/week; 0% reduction, 5 days/week)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Weight-stable diet (0% reduction in energy needs, 7 days/week)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both calorie restriction diets (daily and intermittent)
Number of subjects: 36
Study: 27769310

Group type: EXPERIMENTAL
Intervention: CueS wristband providing 'live' feedback towards pre-set movement goals during a 4-week upper limb therapy programme.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham CueS wristband that monitors upper limb activity but provides no feedback during a 4-week upper limb therapy programme.
Number of subjects: 60
Study: 25539929

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP) 3.0 pmol·kg(‐1)·min(‐1) during a continuous infusion lasting for 4 h
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23033237

Group type: EXPERIMENTAL
Intervention: Closed-loop therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Open-loop therapy
Number of subjects: 10
Study: 20884971

Group type: EXPERIMENTAL
Intervention: Furlong HAC stem
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Furlong Active stem
Number of subjects: 43

Group type: COMPARATOR
Intervention: Both stems
Number of subjects: 43
Study: 17341661

Group type: EXPERIMENTAL
Intervention: Ambulatory postremission strategy (6 consolidation cycles administered monthly in outpatients)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Ambulatory postremission strategy
Number of subjects: 416

Group type: COMPARATOR
Intervention: Intensive strategy (single intensive consolidation course similar to induction)
Number of subjects: 416
Study: 15625656

Group type: COMPARATOR
Intervention: Vitamin E (400 IU/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/day) and pioglitazone (30 mg/day)
Number of subjects: 20
Study: 11171891

Group type: EXPERIMENTAL
Intervention: Acetaminophen plus air blanket therapy (n = 113)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Acetaminophen alone (n = 107)
Number of subjects: 220
Study: 9543597

Group type: EXPERIMENTAL
Intervention: mibefradil
Number of subjects: 143

Group type: COMPARATOR
Intervention: nifedipine SR
Number of subjects: 143
Study: 7851271

Group type: EXPERIMENTAL
Intervention: L-arginine infusion to inhibit tubular reabsorption (TR) of transferrin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: NIDDM patients with microtransferrinuria
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: NIDDM patients with normal TfER
Number of subjects: 64
Study: 3133714

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 45
Study: 30801388

Group type: EXPERIMENTAL
Intervention: Sliding hip screws
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cancellous screws
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 28671553

Group type: EXPERIMENTAL
Intervention: Lamivudine (LVD)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High HBV viral load (>6 log IU/ml) patients in LVD group
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High HBV viral load (>6 log IU/ml) patients in ETV group
Number of subjects: 17
Study: 26987021

Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High polyphenolic cocoa (HP)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: WPI and HP beverages
Number of subjects: 9

Group type: COMPARATOR
Intervention: All beverages
Number of subjects: 9
Study: 24937975

Group type: EXPERIMENTAL
Intervention: Acupuncture performed off-site before and after embryo transfer (n = 57)
Number of subjects: 113

Group type: COMPARATOR
Intervention: No intervention (control group, n = 56)
Number of subjects: 113
Study: 22252354

Group type: EXPERIMENTAL
Intervention: GAA supplementation at 0.6 g/kg
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: GAA supplementation at 1.2 g/kg
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: GAA diets
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: GAA-fed birds
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: 1.2 g/kg GAA
Number of subjects: 768
Study: 20635660

Group type: EXPERIMENTAL
Intervention: Fiber-reinforced composite (FRC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Multistrand stainless steel wire (MSSW)
Number of subjects: 60
Study: 16938155

Group type: EXPERIMENTAL
Intervention: PEEP 10 mbar
Number of subjects: 28

Group type: COMPARATOR
Intervention: PEEP 5 mbar (control)
Number of subjects: 28
Study: 16912577

Group type: EXPERIMENTAL
Intervention: Low-intensity smoking cessation intervention
Number of subjects: 117

Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Intervention cohort
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 117
Study: 12858199

Group type: EXPERIMENTAL
Intervention: Busulfan, melphalan and thiotepa (Bu/Mel/T)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Total body irradiation, cyclophosphamide and etoposide (TBI/CY/E)
Number of subjects: 92
Study: 10577993

Group type: EXPERIMENTAL
Intervention: -344C allele in CYP11B2 gene
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: -344CC homozygous smokers
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: -344TT homozygotes
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Decreased HDL cholesterol level
Number of subjects: 411
Study: 8768511

Group type: EXPERIMENTAL
Intervention: Exposure in vivo followed by cognitive therapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cognitive therapy followed by exposure in vivo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral treatment integrating both strategies from the start
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cognitive-exposure treatment
Number of subjects: 26
Study: 1716340

Group type: EXPERIMENTAL
Intervention: ProMACE-CytaBOM (P-C)
Number of subjects: 179

Group type: COMPARATOR
Intervention: MACOP-B (M-B)
Number of subjects: 179
Study: 6981695

Group type: EXPERIMENTAL
Intervention: Inhaled cephaloridine
Number of subjects: 47

Group type: COMPARATOR
Intervention: No inhaled antibiotic (Control)
Number of subjects: 47
Study: 30451538

Group type: EXPERIMENTAL
Intervention: Amino Acids (AAs) supplementation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Isocaloric glucose (Control)
Number of subjects: 25
Study: 28277415

Group type: EXPERIMENTAL
Intervention: Titrated Hypothermia (32-35°C)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 386
Study: 25943670

Group type: EXPERIMENTAL
Intervention: Internal cooling (ICE, 7.5 g/kg ice slurry ingestion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mixed-methods external cooling (EXT, cold towels, forearm immersion, ice vest, and cooling shorts)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Internal cooling (ICE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mixed-methods external cooling (EXT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cooling (ICE and EXT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cooling (EXT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cooling (ICE)
Number of subjects: 12
Study: 24731903

Group type: EXPERIMENTAL
Intervention: Triple moxibustion (n=15) for 30min
Number of subjects: 30

Group type: COMPARATOR
Intervention: Single moxibustion (n=15) for 10min
Number of subjects: 30
Study: 20932583

Group type: EXPERIMENTAL
Intervention: Ahmed glaucoma valve (AGV)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Baerveldt glaucoma implant (BGI)
Number of subjects: 276
Study: 19363967

Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg, PO single dose)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (tinted oil in clear capsule)
Number of subjects: 31
Study: 17318070

Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 42
Study: 15346539

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan pretreatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: CCK‐4
Number of subjects: 32
Study: 11466983

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9862086

Group type: EXPERIMENTAL
Intervention: Caffeine (1.2 mg/kg, similar to a serving of ground coffee)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Caffeine (1.2 mg/kg, 86 mg, 172 mg, 258 mg total across three doses)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (no caffeine)
Number of subjects: 64
Study: 7604149

Group type: EXPERIMENTAL
Intervention: IV yohimbine (0.4 mg/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 29
Study: 2405827

Group type: EXPERIMENTAL
Intervention: Cryotherapy applied to the avascular retina in one eye or half the eyes depending on severity (18% of patients).
Number of subjects: 279

Group type: COMPARATOR
Intervention: Control group (no cryotherapy).
Number of subjects: 279